CV Science

Frederic Delom Oncology, Gynaecology & Proteostasis Laboratory (OncoGyne)

Course and current status

From 2025 -: Team leader - "Oncology, Gynaecology & ER Stress Laboratory" - Inserm U1312.

2022 - 2024 : Team leader - “Reprograming tumour activity & associated microenvironment” - Inserm U1312.

2016 - 2024 : Head of the research group “AGR, ProTeostasis & Cellular plaSticity” (ARTiSt) laboratory.

From 2016 - : Assistant Professor, University of Bordeaux, Bordeaux.

2011- 2016: University-Inserm chair, University of Bordeaux, Bordeaux

2007 - 2010: Post-doctoral position, Barts and The London, London, UK.

2004 - 2006: Post-doctoral position, McGill University, Montreal, Canada.

2001 - 2004: Scientist position, Aventis Pharmaceutical Company, Paris, France.

1998 - 2001: PhD Thesis, INSERM U38, Marseille, France.

Scientific summary

The OncoGyne team's overarching research theme is to investigate how endoplasmic reticulum stress contributes to cellular reprogramming & adaptation of gynaecological cancers. The team aims to bridge fundamental biological mechanisms with potential clinical applications. The scientific project will be organized around three main axes: 1) understanding the signalling and cellular functions of AGR2, a member of the protein disulphide isomerase (PDI) family (Fundamental axis), 2) evaluating the clinical relevance of these pathways/functions (Translational axis), and 3) developing blocking antibodies to prevent tumour growth and chemotherapy (Preclinical Axis). The team’s strategy aims to establish a continuum from research to clinical application, connecting fundamental discoveries with practical use.
1 - Fundamental axis: The project’s aim is to understand the signalling and cellular functions of AGR2 in gynaecological cancer. Our first aim, is to characterize the molecular network through which AGR2 regulates the cellular reprogramming and the adaptation of gynaecological cancer cells. The second aim is to establish correlations between AGR2 and immune reprogramming into malignant ascites.
2 - Translational axis: The project's translational aim is to assess the clinical relevance of our fundamental research by validating key findings in clinical settings. To support this, we have established a cohort (Baprigyn) and initiated clinical trials.
3 - Preclinical axis: We are currently establishing mouse models of gynaecological cancer for preclinical studies. These models will be used in our proof-of-concept study to develop neutralizing antibodies.